DAFTAR PUSTAKA

1. Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiology. 2024 Nov 13;93:102693. https://doi.org/10.1016/j.canep.2024.102693
2. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019 Jan 22;85(1)
3. Wang Z, Li W, Guo Q, Wang Y, Ma L, Zhang X. Insulin-Like growth factor-1 signaling in lung development and inflammatory lung diseases. BioMed Research International. 2018 Jun 19;2018:1–27. https://doi.org/10.1155/2018/6057589
4. Huang L, Zhou Y, Xu X, Qiu Y, Chen S, Wang S, et al. Different Roles of the Insulin-like Growth Factor (IGF) Axis in Non-small Cell Lung Cancer. CPD. 2022 July;28(25):2052–64. http://dx.doi.org/10.2174/1381612828666220608 122934
5. Zhao J, Wang Z, Wang Z, Zhu L, Liu J, Shi W, et al. Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. OncoTargets and Therapy. 2013 Oct 1;1437. https://doi.org/10.2147/ott.s51997
6. Fu S, Tang H, Liao Y, Xu Q, Liu C, Deng Y, Wang J, Wang J, Fu X. Expression and clinical significance of insulin-like growth factor 1 in lung cancer tissues and perioperative circulation from patients with non-small-cell lung cancer. Curr Oncol. 2016; 23:12–19. https://doi.org/10.3747/ co.23.2669.
7. Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. [Updated 2023 May 8]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK482357/
8. Sadikin B.G. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1438/2023. Jakarta; 2023
9. Soeroso N, Tarigan SP. Faktor Risiko dan Patogenesis: Kanker Paru Diagnosis dan Penatalaksanaan. USU Press. 2017.
10. Malhotra, J., Malvezzi, M., Negri, E., La Vecchia, C., & Boffetta, P. (2016). Risk factors for lung cancer worldwide. *European Respiratory Journal*, *48*(3), 889–902.
11. Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. *Trans Lung Cancer Res*. 2014;3(1):15-22. doi: 10.3978/j.issn.2218-6751.2013.11.03

ɔr-Microenvironment Interactions. In: Dalgleish AG, Haefner B, eds. *veen Inflamation and Cancer*. Volumen 13. Springer; 2006:125-140. ıi.org/10.1007/0-387-26283-0_6

Gazdar A. Pathogenesis of lung cancer signalling pathways: therapies. Eur Respir J. 2009 Jun;33(6):1485-97. doi: 10.1183/014009. PMID: 19483050; PMCID: PMC2762943.

14. Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. *Oncologist*. 2018;23(7):844-848. doi: 10.1634/theoncologist.2017-0659
15. LeRoith D, Holly JMP, Forbes BE. Insulin-like growth factors: Ligands, binding proteins, and receptors. Molecular Metabolism. 2021 Oct 1;52:101245.
16. Argon Y, Bresson SE, Marzec MT, Grimberg A. Glucose-Regulated protein 94 (GRP94): a novel regulator of Insulin-Like growth factor production. Cells. 2020 Aug 6;9(8):1844. https://doi.org/10.3390/cells9081844
17. Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T. Insulin-Like Growth Factor (IGF) pathway targeting in cancer: Role of the IGF axis and opportunities for future combination studies. Targeted Oncology. 2017 Aug 16;12(5):571–97. https://doi.org/10.1007/s11523-017-0514-
18. Shahid A, Santos SG, Lin C, Huang Y. Role of insulin-like growth factor-1 receptor in tobacco Smoking-Associated lung cancer development. Biomedicines. 2024 Mar 2;12(3):563. https://doi.org/10.3390/biomedicines 12030563
19. Hua H, Kong Q, Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. Journal of Hematology & Oncology. 2020 Jun 3;13(1). https://doi.org/10.1186/ s13045-020-00904-3
20. Cao H, Wang G, Meng L, Shen H, Feng Z, Liu Q, et al. Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-Analysis. Shi X, editor. PLoS ONE. 2012 Nov 19;7(11):e49884. http://dx.doi.org/10.1371/journal.pone.0049884
21. Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J. IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp Clin Cancer Res. 2009 Jun 24;28(1):89. doi: 10.1186/1756-9966-28-89. PMID: 19549343; PMCID: PMC2706806.
22. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–35.
23. Nitulescu GM, Van De Venter M, Nitulescu G, Nitulescu G, Ungurianu A, Juzenas P, et al. The Akt pathway in oncology therapy and beyond. Int J Oncol. 2018;53:2319–31.
24. Qin X, Li J, Sun J, Liu L, Chen D, Liu Y. Low shear stress induces ERK nuclear localization and YAP activation to control the proliferation of breast cancer cells. Biochem Biophys Res Commun. 2019;510:219–23.
25. Zhu H, Wang DD, Yuan T, Yan FJ, Zeng CM, Dai XY, et al. Multikinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP [illegible] Res. 2018;78:3995–4006.
Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, et al. Ligand-activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 36–46.
S, Wang M, Zhou L, Zhang Z, Feng X, et al. The caspase-3/ 71. GF-A signaling pathway mediates tumor repopulation during Clin Cancer Res. 2019;25:3732–43.

28. Nurwidya F, Andarini S, Takahashi F, Syahruddin E, Takahashi K. Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer. Malays J Med Sci. 2016 May;23(3):9-21. PMID: 27418865; PMCID: PMC4934714.
29. Karamouzis MV, Papavassiliou AG. The IGF-1 network in lung carcinoma therapeutics. Trends in Molecular Medicine. 2006 Dec 1;12(12):595–602. https://doi.org/10.1016/j.molmed.2006.10.003
30. Pohlman AW, Moudgalya H, Jordano L, Lobato GC, Gerard D, Liptay MJ, et al. The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022 Feb 18;13(1):393–407. doi:10.18632/oncotarget.28202
31. Xu J, Bie F, Wang Y, Chen X, Yan T, Du J. Prognostic value of IGF-1R in lung cancer. Medicine. 2019 May 1;98(19):e15467. https://doi.org/10.1097/md.0000000000015467
32. Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomedical Reports. 2016 Mar 9;4(5):609–14.
33. Kotsantis I, Economopoulou P, Psyrri A, Maratou E, Pectasides D, Gogas H, et al. Prognostic significance of IGF-1 signalling pathway in patients with advanced non-small cell lung cancer. Anticancer Research. 2019 Jul 31;39(8):4185–90.
34. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. The Journal of Clinical Endocrinology
35. De Alcantara Borba D, Da Silva Alves E, Rosa JPP, Facundo LA, Costa CMA, Silva AC, et al. Can IGF-1 Serum Levels Really be Changed by Acute Physical Exercise? A Systematic Review and Meta-Analysis. Journal of Physical Activity and Health. 2020 May 1;17(5):575–84.
36. AsghariHanjani N, Vafa M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. PubMed. 2019 Jan 1;33:56.
37. Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, et al. A structural and functional acromegaly classification. The Journal of Clinical Endocrinology & Metabolism. 2015 Jan 1;100(1):122–31.
38. Lin Z, Shu AD, Bach M, Miller BS, Rogol AD. Average IGF-1 prediction for Once-Weekly lonapegsomatropin in children with growth hormone deficiency. Journal of the Endocrine Society 2021 Nov 8;6(1).
39. Birzniece V, Ho KKY. MECHANISMS IN ENDOCRINOLOGY: Paracrine and endocrine control of the growth hormone axis by estrogen. European Journal of [illegible]y. 2021 Jun 1;184(6):R269–78.
[illegible]A, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. [illegible]e evaluation criteria in solid tumours: Revised RECIST guideline [illegible]). European Journal of Cancer. 2009 Jan;45(2):228–47. [illegible]rg/10.1016/j.ejca.2008. 10.026
[illegible]ller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J [illegible](1):17-48.

42. Ray R, Al Khashali H, Haddad B, Wareham J, Coleman KL, Alomari D, et al. Regulation of Cisplatin Resistance in Lung Cancer Cells by Nicotine, BDNF, and a β-Adrenergic Receptor Blocker. IJMS. 2022 Oct 24;23(21):12829. http://dx.doi.org/ 10. 3390/ijms232112829.
43. Jiang S, Xu Z, Shi Y, Liang S, Jiang X, Xiao M, et al. Circulating insulin-like growth factor-1 and risk of lung diseases: A Mendelian randomization analysis. Front Endocrinol. 2023 Mar 3;14. http://dx.doi.org/10.3389/fendo.2023. 1126397
44. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non–Small cell lung cancer, version 4.2024. Journal of the National Comprehensive Cancer Network. 2024 May 1;22(4):249–74. https://doi.org/10.6004/jnccn. 2204.0023
45. Torelli N, Giacomelli L, Pavanello S. Impact of chronic obstructive pulmonary disease and diabetes on survival in lung cancer patients. BMC Pulm Med. 2016;16:106.
46. Sun X, Wu Y, Gao Y, et al. Serum IGF-1 levels in diabetic patients with non-small cell lung cancer. Mol Clin Oncol. 2018;9(3):321–326.
47. Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes & Diseases. 2015 Mar 1;2(1):13–25. https://doi.org/ 10.1016/j.gendis.2014.10.004
48. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Annals of Oncology. 2009 Jan 20;20(5):842–9. https://doi.org/10.1093/annonc/mdn727